Yoshiki Ishibashi

Dr. Yoshiki Ishibashi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Sleep Health
Verified
Journal Article
Closed access
YIYoshiki Ishibashi
Yoshiki Ishibashi
ASAkiyoshi Shimura
Akiyoshi Shimura

11 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YIYoshiki Ishibashi
Yoshiki Ishibashi
RNRie Nishitani
Rie Nishitani
ASAkiyoshi Shimura
Akiyoshi Shimura
ATAyano Takeuchi
Ayano Takeuchi
MTMamoru Touko
Mamoru Touko
MSMasataka Sasabe
Masataka Sasabe
The aim of this study was to examine the risk of falls associated with the use of non-gamma amino butyric acid (GABA) sleep medications, suvorexant and ramelteon. This case-control and case-crossover study was performed at the Kudanzaka Hospital, Chiyoda Ward, Tokyo. A total of 325 patients who had falls and 1295 controls matched by sex and age were included. The inclusion criteria for the case group were hospitalized patients who had their first fall and that for the control were patients who were hospitalized and did not have a fall, between January 2016 and November 2018. The internal sleep medications administered were classified as suvorexant, ramelteon, non-benzodiazepines, benzodiazepines, or kampo. In the case-control study, age, sex, clinical department, the fall down risk score, and hospitalized duration were adjusted in the logistic regression model. In the case-control study, multivariable logistic regression showed that the use of suvorexant (odds ratio [OR]: 2.61, 95% confidence interval [CI]: 1.29–5.28), nonbenzodiazepines (OR: 2.49, 95% CI: 1.73–3.59), and benzodiazepines (OR: 1.65, 95% CI: 1.16–2.34) was significantly associated with an increased OR of falls. However, the use of ramelteon (OR: 1.40, 95% CI: 0.60–3.16) and kampo (OR: 1.55, 95% CI: 0.75–3.19) was not significantly associated with an increased OR of falls. In the case-crossover study, the use of suvorexant (OR: 1.78, 95% CI: 1.05–3.00) and nonbenzodiazepines (OR: 1.63, 95% CI: 1.17–2.27) was significantly associated with an increased OR of falls. Similar patterns were observed in several sensitivity analyses. It was suggested that suvorexant increases the OR of falls. This result is robust in various analyses. This study showed that the risk of falls also exists for non-GABA sleep medication, suvorexant, and thus it is necessary to carefully prescribe hypnotic drugs under appropriate assessment.


1 March 2021 in Children
Verified
Journal Article
Open access
PDF file
YKYoko Komada
Yoko Komada
YIYoshiki Ishibashi
Yoshiki Ishibashi
SHShunta Hagiwara
Shunta Hagiwara
MKMariko Kobori
Mariko Kobori
ASAkiyoshi Shimura
Akiyoshi Shimura
Excessive daytime sleepiness is increasingly being recognized as a major global health concern. However, there have been few studies related to sleepiness and its associated factors in elementary school children. In Japan, all schools were closed from February to May 2020 to prevent coronavirus disease 2019 (COVID-19) outbreaks. The aim of this study was to identify changes in the subjective sleepiness of pupils during the 1.5-year period and to elucidate factors associated with changes in sleepiness. Questionnaire surveys about pupils’ sleep habits and the Japanese version of the Pediatric Daytime Sleepiness Scale (PDSS-J) were conducted longitudinally at one elementary school in June 2019, January 2020, and June 2020. The average ∆PDSS score was 0.94 ± 5.51 (mean ± standard deviation) from June 2019 to January 2020 and −1.65 ± 5.71 (t[498] = 6.13, p < 0.01) from January 2020 to June 2020. Univariate and multivariate logistic regression analyses revealed that decreasing social jetlag was associated with decreasing PDSS scores (OR = 0.77, 95% CI: 0.62–0.96, p = 0.02) during the school closure. A less restrictive school schedule secondary to a COVID-19-related school closure decreased sleepiness in children and was associated with decreasing social jetlag.

1 January 2024 in Environmental Health and Preventive Medicine
Verified
Journal Article
Open access
PDF file
YIYoshiki Ishibashi
Yoshiki Ishibashi
SHSei Harada
Sei Harada
YEYoko Eitaki
Yoko Eitaki
AKAyako Kurihara
Ayako Kurihara
SKSuzuka Kato
Suzuka Kato
TTToru Takebayashi
Toru Takebayashi
Background: The application of metabolomics-based profiles in environmental epidemiological studies is a promising approach to refine the process of health risk assessment. We aimed to identify potential metabolomics-based profiles in urine and plasma for the detection of relatively low-level cadmium (Cd) exposure in large population-based studies.Method: We analyzed 123 urinary metabolites and 94 plasma metabolites detected in fasting urine and plasma samples collected from 1,412 men and 2,022 women involved in the Tsuruoka Metabolomics Cohort Study. Regression analysis was performed for urinary N-acetyl-beta-D-glucosaminidase (NAG), plasma, and urinary metabolites as dependent variables, and urinary Cd (U-Cd, quartile) as an independent variable. The multivariable regression model included age, gender, systolic blood pressure, smoking, rice intake, BMI, glycated hemoglobin, low-density lipoprotein cholesterol, alcohol consumption, physical activity, educational history, dietary energy intake, urinary Na/K ratio, and uric acid. Pathway-network analysis was carried out to visualize the metabolite networks linked to Cd exposure.Result: Urinary NAG was positively associated with U-Cd, but not at lower concentrations (Q2). Among urinary metabolites in the total population, 45 metabolites showed associations with U-Cd in the unadjusted and adjusted models after adjusting for the multiplicity of comparison with FDR. There were 12 urinary metabolites which showed consistent associations between Cd exposure from Q2 to Q4. Among plasma metabolites, six cations and one anion were positively associated with U-Cd, whereas alanine, creatinine, and isoleucine were negatively associated with U-Cd. Our results were robust by statistical adjustment of various confounders. Pathway-network analysis revealed metabolites and upstream regulator changes associated with mitochondria (ACACB, UCP2, and metabolites related to the TCA cycle).Conclusion: These results suggested that U-Cd was associated with metabolites related to upstream mitochondrial dysfunction in a dose-dependent manner. Our data will help develop environmental Cd exposure profiles for human populations.

13 January 2021 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
PDF file
YIYoshiki Ishibashi
Yoshiki Ishibashi
RNRie Nishitani
Rie Nishitani
TKTakashi Kato
Takashi Kato
SCSahoko Chiba
Sahoko Chiba
KAKeiko Ashidate
Keiko Ashidate
MSMasataka Sasabe
Masataka Sasabe